Skip to main content
. 2006 Dec 4;27(4):1455–1466. doi: 10.1128/MCB.01369-06

FIG. 5.

FIG. 5.

Reduced mortality after myocardial infarction in response to p38 MAPK inhibition. SB202190, a p38α and -β inhibitor, was injected intraperitoneally into wild-type and 14-3-3τ+/− animals (5 mg/kg/day). A. Reduced cardiac p38 MAPK activity in 14-3-3τ+/− mice injected with SB202190. Protein lysates were generated from hearts taken from mice injected daily with SB202190 (SB) or vehicle for 8 days. Cardiac lysates were analyzed by anti-phospho-p38 MAPK and anti-phospho-ATF2 immunoblotting. Anti-total-ERK MAPK immunoblotting was performed to control for protein loading. B. SB202190 treatment increases survival for 14-3-3τ+/− mice after MI. Left coronary artery ligation was performed after 3 days of SB202190 administration. The increased survival of 14-3-3τ+/− mice injected with SB202190 compared to mice injected with vehicle was statistically significant by the log-rank test (76% versus 46%; P = 0.046).